Summary
Adult patients with metabolic myopathies typically present with exercise-induced pain, cramps, fatigue, and myoglobinuria. The current therapeutic options of glycogen and lipid storage myopathies include dietary treatments, excersise training, and pharmacological supplementations. Herein is a review of evidence from randomized controlled trials in McArdle disease (glycogen storage disease type V, muscle phosphorylase deficiency) and carnitine palmitoyltransferase (CPT) 2 deficiency. A brief overview on current treatment options in rhabdomyolysis is also included because patients with McArdle disease and CPT 2 often experience such potentially life-threatening complications.
Key Words: McArdle disease, rhabdomyolysis, metabolic myopathy, carnitine palmitoyltransferase (CPT) 2 deficiency, glycogen storage disease, lipid storage disease
References
- 1.Quinlivan R, Vissing J. 144th ENMC International Workshop: outcome measures in McArdle disease. Neuromuscul Disord. 2007;17:494–498. doi: 10.1016/j.nmd.2007.03.001. [DOI] [PubMed] [Google Scholar]
- 2.Quinlivan R, Beynon RJ, Martinuzzi A. Pharmacological and nutritional treatment for McArdle disease (glycogen storage disease type V) Cochrane Database Syst Rev. 2008;2:CD003458–CD003458. doi: 10.1002/14651858.CD003458.pub3. [DOI] [PubMed] [Google Scholar]
- 3.Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J. Carnitine palmitoyltransferase 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med. 2004;25:495–520. doi: 10.1016/j.mam.2004.06.004. [DOI] [PubMed] [Google Scholar]
- 4.Kley RA, Vorgerd M, Tarnopolsky M. Creatine for treating muscle disorders. Cochrane Database Syst Rev. 2007;1:CD004760–CD004760. doi: 10.1002/14651858.CD004760.pub2. [DOI] [PubMed] [Google Scholar]
- 5.Willott CA, Young ME, Leighton B, et al. Creatine uptake in isolated soleus muscle: kinetics and dependence on sodium, but not on insulin. Acta Physiol Scand. 1999;166:99–104. doi: 10.1046/j.1365-201x.1999.00539.x. [DOI] [PubMed] [Google Scholar]
- 6.Vorgerd M, Grehl T, Jager M, et al. Creatine therapy in myophosphorylase deficiency (McArdle’s disease): a placebo controlled crossover trial. Arch Neurol. 2000;57:956–963. doi: 10.1001/archneur.57.7.956. [DOI] [PubMed] [Google Scholar]
- 7.Vorgerd M, Zange J, Kley R, et al. Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle’s disease: double-blind, placebo-controlled crossover trial. Arch Neurol. 2002;59:97–101. doi: 10.1001/archneur.59.1.97. [DOI] [PubMed] [Google Scholar]
- 8.Andersen ST, Vissing J. Carbohydrate- and protein-rich diets in McArdle disease: effect on exercise capacity. J Neurol Neurosurg Psychiatry 2008 Jun 5; [Epub ahead of print]. [DOI] [PubMed]
- 9.Haller RG, Wyrick MA, Taivassalo T, Vissing J. Aerobic conditioning: an effective therapy in McArdle’s disease. Ann Neurol. 2006;59:922–928. doi: 10.1002/ana.20881. [DOI] [PubMed] [Google Scholar]
- 10.Martinuzzi A, Sartori E, Fanin M, et al. Phenoytype modulators in myophosphorylase deficiency. Ann Neurol. 2003;53:497–502. doi: 10.1002/ana.10499. [DOI] [PubMed] [Google Scholar]
- 11.Rubio JC, Gómez-Gallego F, Santigao C, et al. Genotype modulators of clinical severity in McArdle disease. Neurosci Lett. 2007;422:217–222. doi: 10.1016/j.neulet.2007.06.025. [DOI] [PubMed] [Google Scholar]
- 12.Martinuzzi A, Liava A, Trevisi E, et al. Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle’s disease. Muscle Nerve. 2008;37:350–357. doi: 10.1002/mus.20937. [DOI] [PubMed] [Google Scholar]
- 13.Schroers A, Kley RA, Stachon A, et al. Gentamicin treatment in McArdle disease: failure to correct myophosphorylase deficiency. Neurology. 2006;66:285–286. doi: 10.1212/01.wnl.0000194212.31318.fc. [DOI] [PubMed] [Google Scholar]
- 14.Andersen ST, Haller RG, Vissing J. Effect of oral sucrose shortly before exercise on work capacity in McArdle disease. Arch Neurol. 2008;65:786–789. doi: 10.1001/archneur.65.6.786. [DOI] [PubMed] [Google Scholar]
- 15.Orngreen MC, Olsen DB, Vissing J. Exercise tolerance in carnitine palmitoyltransferase II deficiency with IV and oral glucose. Neurology. 2002;59:1046–1051. doi: 10.1212/WNL.59.7.1046. [DOI] [PubMed] [Google Scholar]
- 16.Orngreen MC, Ejstrup R, Vissing J. Effect of diet on exercise intolerance in carnitine palmitoyltransferase II deficiency. Neurology. 2003;61:559–561. doi: 10.1212/01.WNL.0000078195.05396.20. [DOI] [PubMed] [Google Scholar]
- 17.Djouadi F, Bonnefont JP, Thuillier L, et al. Correction of fatty acid oxidation in carnitine palmitoyltransferase 2-deficient cultured skin fibroblasts by bezafibrate. Pediatr Res. 2003;54:446–451. doi: 10.1203/01.PDR.0000083001.91588.BB. [DOI] [PubMed] [Google Scholar]
- 18.Djouadi F, Aubey F, Schlemmer D, Bastin J. Peroxisome proliferator activated receptor delta (PPARdelta) agonist but not PPARalpha corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells. J Clin Endocrinol Metab. 2005;90:1791–1797. doi: 10.1210/jc.2004-1936. [DOI] [PubMed] [Google Scholar]
- 19.Roe CR, Sweetman L, Roe DS, David F, Brunengraber H. Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest. 2002;110:259–269. doi: 10.1172/JCI0215311. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Roe CR, Mochel F. Anaplerotic diet therapy in inherited metabolic disease: therapeutic potential. J Inherit Metab Dis. 2006;29:332–340. doi: 10.1007/s10545-006-0290-3. [DOI] [PubMed] [Google Scholar]
- 21.Huerta-Alardin AL, Varon J, Marik PE. Bench-to-bedside review: Rhabdomyolysis—an overview for clinicians. Crit Care. 2005;9:158–169. doi: 10.1186/cc2978. [DOI] [PMC free article] [PubMed] [Google Scholar]